StockData
Evofem Biosciences, Inc. logo

Evofem Biosciences, Inc. (EVFM) stock

EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.01−0.00 (-10.00%)

Close on Oct 19, 2026Market cap $865.23KP/E –Yield –

Evofem Biosciences operating margin

Operating margin is operating income as a percentage of revenue.

Evofem Biosciences's operating margin for the twelve months ending Jun 30, 2026 was -15.3%. For fiscal 2025 it was 16.7%, against -39.6% the year before. The highest annual figure on record is 16.7% in fiscal 2025.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202516.7%+56.3
FY2024Dec 31, 2024-39.6%+58.3
FY2023Dec 31, 2023-98.0%+401.7
FY2022Dec 31, 2022-499.6%+1523.7
FY2021Dec 31, 2021-2023.3%+21210.8
FY2020Dec 31, 2020-23234.1%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-94.5%−68.6
Q1 FY2026Mar 31, 2026-508.2%−546.9
Q4 FY2025Dec 31, 202535.0%+49.1
Q3 FY2025Sep 30, 202519.2%+73.5
Q2 FY2025Jun 30, 2025-25.9%+7.5
Q1 FY2025Mar 31, 202538.7%+117.6
Q4 FY2024Dec 31, 2024-14.1%+284.3
Q3 FY2024Sep 30, 2024-54.3%+7.3
Q2 FY2024Jun 30, 2024-33.4%+6625.2
Q1 FY2024Mar 31, 2024-78.9%+215.0
Q2 FY2023Jun 30, 2023-298.5%+106.2
Q1 FY2023Mar 31, 2023-61.6%+618.9
Q4 FY2022Dec 31, 2022-6658.6%−5610.4
Q3 FY2022Sep 30, 2022-293.9%+2239.3
Q2 FY2022Jun 30, 2022-404.7%+1810.8
Q1 FY2022Mar 31, 2022-680.5%+3380.3
Q4 FY2021Dec 31, 2021-1048.1%+20291.8
Q3 FY2021Sep 30, 2021-2533.2%+6875.4
Q2 FY2021Jun 30, 2021-2215.5%–
Q1 FY2021Mar 31, 2021-4060.8%–
Q4 FY2020Dec 31, 2020-21339.9%–
Q3 FY2020Sep 30, 2020-9408.6%–

More Evofem Biosciences figures

See a number that looks wrong?